156 related articles for article (PubMed ID: 7579407)
1. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.
Lu ZY; Brailly H; Wijdenes J; Bataille R; Rossi JF; Klein B
Blood; 1995 Oct; 86(8):3123-31. PubMed ID: 7579407
[TBL] [Abstract][Full Text] [Related]
2. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma.
Bataille R; Barlogie B; Lu ZY; Rossi JF; Lavabre-Bertrand T; Beck T; Wijdenes J; Brochier J; Klein B
Blood; 1995 Jul; 86(2):685-91. PubMed ID: 7605999
[TBL] [Abstract][Full Text] [Related]
3. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo.
Lu ZY; Brochier J; Wijdenes J; Brailly H; Bataille R; Klein B
Eur J Immunol; 1992 Nov; 22(11):2819-24. PubMed ID: 1425909
[TBL] [Abstract][Full Text] [Related]
4. Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines.
Drexler HG; Meyer C; Gaidano G; Carbone A
Leukemia; 1999 Apr; 13(4):634-40. PubMed ID: 10214873
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting IL-6 in human multiple myeloma.
Klein B; Lu ZY; Gaillard JP; Harousseau JL; Bataille R
Curr Top Microbiol Immunol; 1992; 182():237-44. PubMed ID: 1490360
[No Abstract] [Full Text] [Related]
6. Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis.
Lu ZY; Brailly H; Rossi JF; Wijdenes J; Bataille R; Klein B
Cytokine; 1993 Nov; 5(6):578-82. PubMed ID: 8186369
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulating IL-6 activity by murine monoclonal antibodies.
Brochier J; Legouffe E; Liautard J; Gaillard JP; Mao LQ; Bataille R; Rossi JF; Klein B
Int J Immunopharmacol; 1995 Jan; 17(1):41-8. PubMed ID: 7782152
[TBL] [Abstract][Full Text] [Related]
8. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
9. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.
van Zaanen HC; Koopmans RP; Aarden LA; Rensink HJ; Stouthard JM; Warnaar SO; Lokhorst HM; van Oers MH
J Clin Invest; 1996 Sep; 98(6):1441-8. PubMed ID: 8823310
[TBL] [Abstract][Full Text] [Related]
10. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6.
Legouffe E; Liautard J; Gaillard JP; Rossi JF; Wijdenes J; Bataille R; Klein B; Brochier J
Clin Exp Immunol; 1994 Nov; 98(2):323-9. PubMed ID: 7955540
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
[TBL] [Abstract][Full Text] [Related]
12. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.
Trikha M; Corringham R; Klein B; Rossi JF
Clin Cancer Res; 2003 Oct; 9(13):4653-65. PubMed ID: 14581334
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.
Westendorf JJ; Ahmann GJ; Greipp PR; Witzig TE; Lust JA; Jelinek DF
Leukemia; 1996 May; 10(5):866-76. PubMed ID: 8656685
[TBL] [Abstract][Full Text] [Related]
14. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells.
Ozaki S; Kosaka M; Wakahara Y; Ozaki Y; Tsuchiya M; Koishihara Y; Goto T; Matsumoto T
Blood; 1999 Jun; 93(11):3922-30. PubMed ID: 10339501
[TBL] [Abstract][Full Text] [Related]
15. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
Suzuki H; Yasukawa K; Saito T; Goitsuka R; Hasegawa A; Ohsugi Y; Taga T; Kishimoto T
Eur J Immunol; 1992 Aug; 22(8):1989-93. PubMed ID: 1639101
[TBL] [Abstract][Full Text] [Related]
16. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.
Van Zaanen HC; Lokhorst HM; Aarden LA; Rensink HJ; Warnaar SO; Van Oers MH
Leuk Lymphoma; 1998 Nov; 31(5-6):551-8. PubMed ID: 9922045
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes.
Yap SH; Moshage HJ; Hazenberg BP; Roelofs HM; Bijzet J; Limburg PC; Aarden LA; van Rijswijk MH
Biochim Biophys Acta; 1991 Feb; 1091(3):405-8. PubMed ID: 2001421
[TBL] [Abstract][Full Text] [Related]
18. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms.
Emilie D; Wijdenes J; Gisselbrecht C; Jarrousse B; Billaud E; Blay JY; Gabarre J; Gaillard JP; Brochier J; Raphael M
Blood; 1994 Oct; 84(8):2472-9. PubMed ID: 7919367
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.
Rossi JF; Fegueux N; Lu ZY; Legouffe E; Exbrayat C; Bozonnat MC; Navarro R; Lopez E; Quittet P; Daures JP; Rouillé V; Kanouni T; Widjenes J; Klein B
Bone Marrow Transplant; 2005 Nov; 36(9):771-9. PubMed ID: 16113665
[TBL] [Abstract][Full Text] [Related]
20. Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-beta.
Taylor AW; Ku NO; Mortensen RF
J Immunol; 1990 Oct; 145(8):2507-13. PubMed ID: 2170518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
